Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13158015 | 1.00 | ATM (0.47) | ATMKDM4EMEN1KMT2ASLC18A3 | |
| SCHEMBL3109764 | 0.89 | F10 (0.50) | ATMKDM4ESLC18A3ALDH1A1MAPT | |
| SCHEMBL13157849 | 0.87 | KMT2A (0.52) | MEN1KMT2ASLC18A3POLBALDH1A1 | |
| SCHEMBL3098323 | 0.87 | KMT2A (0.52) | MEN1KMT2ASLC18A3POLBALDH1A1 | |
| SCHEMBL3100951 | 0.87 | KMT2A (0.52) | MEN1KMT2ASLC18A3POLBALDH1A1 | |
| SCHEMBL13157952 | 0.87 | KMT2A (0.52) | MEN1KMT2ASLC18A3POLBALDH1A1 | |
| SCHEMBL13158012 | 0.86 | POLB (0.46) | KDM4EMEN1KMT2ASLC18A3POLB | |
| SCHEMBL3108317 | 0.86 | POLB (0.46) | KDM4EMEN1KMT2ASLC18A3POLB | |
| SCHEMBL13157845 | 0.86 | MGLL (0.46) | MEN1KMT2ASLC18A3POLBALDH1A1 | |
| SCHEMBL3107797 | 0.86 | MGLL (0.46) | MEN1KMT2ASLC18A3POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399455-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | ACKR3, CCR5, CXCR2 | ATM 4099/4885KDM4E 4629/4885MEN1 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.